Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245312 | 0.90 | MET (0.44) | METLMNATSHRHTTSMN1; SMN2 | |
| SCHEMBL12224229 | 0.90 | SMN1; SMN2 (0.48) | METLMNATSHRHTTSMN1; SMN2 | |
| SCHEMBL12224243 | 0.90 | MET (0.47) | METLMNATSHRHTTSMN1; SMN2 | |
| SCHEMBL12224215 | 0.87 | MET (0.46) | METKDM4EHPGDHSD17B10 | |
| SCHEMBL14715596 | 0.85 | MET (0.40) | MET | |
| SCHEMBL12224212 | 0.85 | LMNA (0.44) | METLMNATSHRHTTSMN1; SMN2 | |
| SCHEMBL12224242 | 0.83 | MET (0.41) | METLMNATSHRHTTSMN1; SMN2 | |
| SCHEMBL12730591 | 0.81 | MET (0.43) | METKDM4E | |
| SCHEMBL14715539 | 0.81 | MET (0.39) | MET | |
| SCHEMBL2452860 | 0.81 | MET (0.40) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367827-B1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4]TRIAZOLO [4,3-b]PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | claimed |
| US-8426397-B2 | 3 (3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8426397-B2 | 3 (3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8426397-B2 | 3 (3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-23 | — | — | US | disclosed |
| EP-2367827-B1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4]TRIAZOLO [4,3-b]PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2367827-B1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4]TRIAZOLO [4,3-b]PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-20110257173-A1 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK PATENT GMBH MIT BESCHRAENKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257173-A1 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK PATENT GMBH MIT BESCHRAENKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257173-A1 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK PATENT GMBH MIT BESCHRAENKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-2367827-A1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-Ý1,2,4¨TRIAZOLO Ý4,3-B¨PYRIDAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010072301-A1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072301-A1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257173-A1 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | RET, ERBB2, JAK2 | MET 5/4885LMNA 3527/4885TSHR 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.